Citation: Ae. Stephen et al., Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo, P NAS US, 98(6), 2001, pp. 3214-3219
Authors:
Segev, DL
Hoshiya, Y
Stephen, AE
Hoshiya, M
Tran, TT
MacLaughlin, DT
Donahoe, PK
Maheswaran, S
Citation: Dl. Segev et al., Mullerian inhibiting substance regulates NF kappa B signaling and growth of mammary epithelial cells in vivo, J BIOL CHEM, 276(29), 2001, pp. 26799-26806
Citation: Dt. Maclaughlin et al., Perspective: Reproductive tract development - New discoveries and future directions, ENDOCRINOL, 142(6), 2001, pp. 2167-2172
Authors:
Segev, DL
Ha, TU
Tran, TT
Kenneally, M
Harkin, P
Jung, M
MacLaughlin, DT
Donahoe, PK
Maheswaran, S
Citation: Dl. Segev et al., Mullerian inhibiting substance inhibits breast cancer cell growth through an NF kappa B-mediated pathway, J BIOL CHEM, 275(37), 2000, pp. 28371-28379
Authors:
Masiakos, PT
MacLaughlin, DT
Maheswaran, S
Teixeira, J
Fuller, AF
Shah, PC
Kehas, DJ
Kenneally, MK
Dombkowski, DM
Ha, TU
Preffer, FI
Donahoe, PK
Citation: Pt. Masiakos et al., Human ovarian cancer, cell lines, and primary ascites cells express the human mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS, CLIN CANC R, 5(11), 1999, pp. 3488-3499
Authors:
Gu, ZY
Reynolds, EM
Song, JH
Lei, H
Feijen, A
Yu, LA
He, WW
MacLaughlin, DT
van den Eijnden-van Raaij, J
Donahoe, PK
Li, E
Citation: Zy. Gu et al., The type I serine threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo, DEVELOPMENT, 126(11), 1999, pp. 2551-2561
Authors:
Lane, AH
Lee, MM
Fuller, AF
Kehas, DJ
Donahoe, PK
MacLaughlin, DT
Citation: Ah. Lane et al., Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors, GYNECOL ONC, 73(1), 1999, pp. 51-55